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CASE PRESENTATION
A 27-year-old transplant patient was admitted to the Hospital Privado-
Centro Medico de COrdoba for a core decompression procedure on both
femoral heads and a bone biopsy of the iliac crest. He had received a
cadaveric graft 18 months prior to this admission after receiving chronic
hemodialysis for 14 months. His renal failure was due to chronic glonier-
ulonephritis of undefined cause. At the time of transplantation, his intact
PTH serum level was 132 pg/dl and the serum aluminum concentration
was 139.6 g/liter (Table 1). He was given immunosuppression therapy of
steroids and cyclosporine. Diuresis began on the seventh postoperative
day after a period of presumed acute tubular necrosis. Acute rejection
(Banif I/lI on the biopsy specimen) occurred on postoperative day 12, and
he was given a series of intravenous boluses of methylprednisolonc (250
mg twice daily for 3 days). The rejection resolved and he was discharged
from the hospital on postoperative day 20; his serum creatinine was 2.2
mgldl.
He pursued most of his previous activities, but 15 months after
transplantation hc started to complain of pain in both hips. Radiographic
examination disclosed no abnormalities. A bone scan showed a moderate
and diffuse increase in uptake of the tracer, compatible with hyperpara-
thyroidism, but no focal hot areas. He was treated with analgesics and
advised to refrain from physical activity. Two months later, his symptoms
worsened, and subtle radiologic changes were evident on both femoral
heads. A nuclear magnetic resonance (NMR) imaging study showed clear
evidence of bilateral osteonecrosis. His symptoms immediately disap-
peared after core decompression of both hips, and he was discharged but
advised to use crutches and limit his walking for 3 months. Iliac crest bone
biopsy findings disclosed resolving osteomalacia with increased osteoclas-
tic activity and a few small deposits of aluminum. Bone aluminum content
was 14.7 J.rg/g. Six months after the core decompression, he was free of
symptoms. An NMR study showed consolidation of the lesion on the right
hip but clear evidence of progression on the left side.
DISCUSSION
DR. PABLO U. MASSARI (Chief Renal Service, Hospital Privado-
Centro Medico de Córdoba, and Professor of Medicine, Catholic
University of Córdoba, Córdoba, Argentina): This young patient
with chronic renal failure received a successful cadaveric renal
transplant after a relatively short period on the waiting list. After
transplantation he experienced several of the bone and mineral
problems known to occur in this condition (Table 2); these
abnormalities have been reviewed elsewhere [1, 2]. At the time of
transplantation, he had evidence of aluminum overload and
probably low-turnover bone disease, as indicated by low serum
PTH (132 pg/dl) and alkaline phosphatase levels (55 lU/liter) and
a high serum concentration of aluminum (139.6 itg/liter). Within
two weeks after transplantation, both PTH and alkaline phospha-
tase levels rose and the serum aluminum declined rapidly in
association with persistent urinary aluminum excretion. Later,
while otherwise doing well clinically, he was struck by one of the
most debilitating bone conditions in a renal transplant patient:
avascular bone necrosis of the femoral heads.
Post-transplant bone and mineral disorders could be classified,
according to their pathogenesis and appearance time, into two
groups of entities: those bone disorders related to pre-transplant
renal osteodystrophy that persist after transplantation, and those
arising de novo after appropriate renal function has been restored
(Table 2). Overlapping of these disorders is not rare. I will review
both types of syndromes with a focus on the problems suffered by
the patient presented today. Normalization of changes in mineral
and bone metabolism and structure do not occur as fast as other
metabolic processes do after renal function is restored. Conse-
quently, bone conditions present before transplantation can per-
sist for prolonged periods and can become symptomatic before
their complete reversal. These persistent pre-transpiant disorders
are: hyperparathyroidism (HPT), aluminum bone disease, and
dialysis-related amyloid bone disease.
Persistent pre-transpiant disorders
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Hyperparathyroidism. When a renal graft starts to function
properly, it does so in a setting characterized by: (1) negative
calcium and positive phosphate balances that had been only
partially and intermittently corrected by dialysis and administra-
tion of calcitriol and oral calcium [2]; (2) low production of
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Table 1. Serum and urinary biochemical values and immunosuppressive
drug doses
Pre-transplant Day 15 Day 30 Day 90 18 months
Serum
Creatinine, mg/dl 12.8 3.8 2 1.8 1.4
Calcium, mg/dl 9.2 8.4 9.8 9.5 9.4
Phosphate, mg/dl 4.8 2.8 3.3 1.9 3
Alkaline phosphatase, 55 89 92 128 279
lU/liter
Intact PTH,pg/ml 132 430 250 128 100
Aluminum, pg/liter 139.6 105 73.8 36.6 —
Urine
Aluminum, pg/liter — 153.8 249.1 145.4 —
Aluminum/creatinine, — 2.84 2.73 1.04 —
pg/mg
Immunosuppression
Prednisone, mg/day 500k' 45 25 10
Cyclosporinc, mg/day — 520 320 300 240
61% as bone alkaline phosphatase.
As i.v. pulses of mcthylprednisolonc X 3 days.
calcitriol and impediments to the genomic and non-genomic
actions of the hormone [3]; (3) continuous stimulation of PTH
synthesis and secretion due to overexpression of the PTH gene in
parathyroid cells, recruitment of more cells into an active secre-
tory state, and hypertrophy and hyperplasia of the parathyroid
gland [4]; and (4) resistance to the calcemic action of PTH [11.
Normalization of glomerular filtration and tubular function rap-
idly eliminates phosphate and uremic toxins and restores effective
calcitriol production, all of which contribute to reversing the
preceding abnormalities and suppress parathyroid gland hyper-
function. But securing the involution of parathyroid gland hyper-
plasia is neither rapid nor easy; it can take months or even years
to normalize the size of the glands and reach basal PTH secretion
[51. Moreover, glands with nodular hyperplasia, which are known
to have reduced density of calcitriol receptors [6] and which
probably have low expression of the membrane calcium sensor
receptor [7], especially those with monoclonal proliferation, might
never return to normal size and function [I. McCarron et al
studied 15 patients with post-transplant HPT, giving intravenous
infusions of calcium and EDTA to evaluate the parathyroid
function curve [8]. Patients with post-transplant HPT displayed a
curve with a slope similar to normals but with a shift to the right,
indicating a conserved sensitivity to extracellular calcium concen-
tration but augmented basal PTH secretion. The same group also
demonstrated that basal PTH secretion correlates with gland size
[9].
Several other factors can influence the involution of HPT in
these patients. Duration and intensity of pre-transplant HPT
correlates positively with the time-course and severity of persis-
tent post-transplant HPT [101. Also, we have recently shown that
pre-transplant aluminum overload can influence post-transplant
parathyroid function, especially during the early post-transplant
months [11]. Moreover, continuous production of calcitriol in
normal amounts by the graft seems to be a key factor in the
involution of HPT [12]. Serum calcitriol levels correlate well with
graft function and consequently calcitriol production might not he
sufficient to inhibit PTH secretion in patients with poor initial
function [131. Steiner and colleagues demonstrated a marked
decrease in both N-terminal and C-terminal levels in a group of 10
stable normocalcemic hyperparathyroid renal transplant patients
Table 2. Disorders of bone and mineral metabolism after renal
transplantation
Persistent pre-transplant disorders
Hyperparathyroidism
Aluminum bone disease
Dialysis-related amyloid bone disease
Dc novo bone and mineral disorders
Renal tubular dysfunction
Renal tubular acidosis
Renal tubular hypercalciuria
Non-PTH-related hypophosphatemia
Painful legs syndrome
Avascular hone necrosis
Immunosuppression-related bone disease (drugs and cytokine-
induced)
after an average of 5 months on vitamin D and calcium therapy
[14]. Finally, the use of drugs that can impair intestinal calcium
absorption (steroids) [151 or block calcitriol synthesis (ketocon-
azol) [16] also can interfere with the involution of HPT after renal
transplantation.
Persistent HPT, perhaps the most common mineral disturbance
in the transplant patient, is almost invariably present in the early
post-transplant period [5, 10, 17, 18], but it generally resolves in a
few months. Hypercalcemia, usually of mild degree and without
clinical consequences, is its most frequent biochemical marker. In
our experience, 23% of 47 consecutive transplant patients devel-
oped hypercalcemia within the first three months (Fig. 1) [18], but
the calcium level exceeded 12 mg/dl in only 10%; the hypercalce-
mia was self-limited in every case, as it resolved spontaneously
before the first year after transplantation. Most of the patients
with post-transplant hypercalcemia also had elevated serum PTH
levels, but it is notable that 4 of our hypercalcemic patients (2 at
day 30 and 2 at day 60 post transplantation) had low values of
PTH concomitantly with a high serum aluminum concentration
[18]. Rarely, hypercalcemia exceeds 13 mg/dl and/or can have a
protracted course, becoming symptomatic and eventually compro-
mising graft function [19]. This syndrome is usually seen in
patients with severe, uncontrolled pre-transplant HPT [5]. They
rarely require surgical treatment and are best served by conser-
vative measures and by avoiding fluid deprivation and adminis-
tration of agents that can worsen hypercalcemia, such as oral
calcium and vitamin D supplements, and thiazide diuretics.
Hypophosphatemia, another manifestation of persistent HPT,
has a higher incidence than hypercaleemia (30% versus 50%) [181
during the first year after transplantation because of the coexist-
ence of non-PTH-mediated phosphaturia [20]. Two decades ago,
post-transplant hypophosphatemia was associated with osteoma-
lacia [21], hut more recent observations have not revealed osteo-
malacia in bone biopsy specimens from patients with post-
transplant hypophosphatemic HPT [22]. Using nuclear magnetic
resonance spectroscopy, Higgins et al found evidence that deple-
tion of intracellular phosphate compounds and the use of steroids
are associated with the development of hypophosphatemia [23].
This observation is important in relation to the pathogenesis of
hypophosphatemic and steroid-induced myopathy. Protracted
post-transplant hypophosphatemia might require oral or intrave-
nous phosphate replacement to prevent osteomalacia and myop-
athy. Steiner et al [141 and Dumoulin et al [24] have shown that
oral calcium and vitamin D supplements can reduce PTH levels
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Fig. 1. Distribution of serum calcium and
simultaneous PTH levels at 30, 60, and 90 post-
transplant days in 47 consecutive patients.
Rectangle indicates normal values.
and increase renal tubular phosphate reabsorption in patients
with normolcalcemic, hypophosphatemic, post-transplant HPT.
What are the indications for surgical treatment of post-trans-
plant HPT? It seems advisable to consider subtotal parathyroid-
ectomy or ethanol injection only for patients with symptomatic,
protracted hypercalcemia; deterioration of graft function; or
soft-tissue calcifications and worsening bone disease. All these
sequelae are rare in today's transplant experience [19, 25, 261.
Aluminum bone disease. A 1993 report indicated that the
incidence of aluminum-related bone disease in patients with
chronic renal failure who receive dialysis treatment is decreasing
[27], but this entity has not disappeared. Aluminum accumulation
still occurs as a major finding or in combination with other types
of renal osteodystrophy in large reported series of bone biopsies
in dialysis patients [27—291. Moreover, overexposure to aluminum
from contaminated dialysate (that is, high levels of aluminum in
the water supply used to prepare the dialysate) seems to be quite
prevalent in South America. We recently found that 57% of 47
consecutive transplant patients had serum aluminum levels higher
than 40 .tg/liter just prior to transplantation [ii], as did the
patient presented today. Although serum levels are not a good
marker of aluminum bone disease [30], the high and prolonged
rate of urinary aluminum excretion shown by today's patient
(Table 1) is certainly a good indicator of the whole-body alumi-
num burden [31, 32]. Moreover, 18 months after transplantation,
a bone biopsy in our patient disclosed evidence of recovering
osteomalacia and an elevated bone aluminum content. Several
reports have shown that renal transplantation is a successful
therapy for aluminum-related bone disease, but it takes probably
longer than one year to significantly reduce bone aluminum
content [33—35].
Besides bone disease, aluminum intoxication is associated with
an increased risk of soft-tissue calcium deposition [28] and, more
important, more shortened survival in dialysis patients [28, 36].
Also, patients with aluminum intoxication have an increased
incidence of infectious complications after transplantation [37,
381. Therefore, it seems advisable to increase urinary aluminum
Fig. 2. Effect of an acute oral load of potassium citrate on urinary
excretion of citrate and aluminum in renal transplant patients (n = 8).
Values shown are mean 1 SE.
elimination in transplant patients. In 1984, Malluche et a! accom-
plished this by administering deferoxamine [39], but deferoxamine
therapy is not without risks, and it involves repeated intravenous
administration.
Urinary aluminum elimination increases dramatically during
the immediate post-transplant period. This rise occurs contempo-
raneously and correlates positively with urinary phosphate excre-
tion. We believe that this correlation also might have therapeutic
implications [40]. Because a recent experimental model in the rat
suggested that citrate can increase urinary aluminum excretion
[41], we are currently testing a protocol of oral potassium citrate
administration in transplant patients. Very preliminary results
show a marked increase in urinary aluminum excretion after a
single dose (Fig, 2). If more detailed and extended studies confirm
this approach, potassium citrate administration would seem to be
an easy and rational way to accelerate aluminum detoxification in
these patients.
Dialysis-related amyloid bone disease. Cystic bone lesions sec-
ondary to deposition of fibrillar beta amyloid in periarticular bone
is the most recently described form of renal osteodystrophy [42].
I will only mention here that transplantation produces a rapid
disappearance of symptoms but that the cystic lesions persist for
many years [43—45]. We need more information on the natural
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history of this disorder after transplantation and its relationship
with increased production and high blood levels of beta-2 micro-
globulin (46].
After transplantation, complications can develop that are par-
ticular to the patient with a functioning graft. Several tubular
dysfunctions can alter mineral metabolism in these patients, such
as renal tubular acidosis [47, 48], renal hypercalciuria [49], and
non-PTH-related hypophosphatemia [20]. 1 will not discuss these
syndromes today; instead we shall move on to other, more
prevalent and clinically disabling entities.
Post-transplant disorders
Painful legs 5yndrome. This syndrome, described in recent years
in transplant patients [50—54], includes pain over the long bones,
mostly localized to the knees and ankles, without evidence of joint
inflammation. The pain is often symmetrical, interferes with
walking, is not relieved by rest, and often awakens the patient at
night. The leg pain arises during the first or second month after
transplantation and resolves spontaneously in a few weeks. Occa-
sionally, patients have the symptoms for more than a year. The
real frequency of the syndrome is unknown. Informal communi-
cation with several transplant centers leads to the impression that
in its mild and very transient form, the syndrome is quite common.
However, the incidence of the "full-blown" picture has been
approximately 10% in some series [50, 51]. Lucas et al found a
clear relationship between the appearance of the painful legs
syndrome and the initiation of cyclosporine therapy [50]. Others
also have implicated cyclosporine based on the fact that symptoms
improved with administration of vasodilating calcium-channel
blockers [53]. Plain radiographs of bones, as well as bone scans,
are of no diagnostic value. Magnetic resonance imaging shows
changes compatible with so-called stress or insufficiency fractures
[52], and epiphyseal impaction has been suggested as the under-
lying structural abnormality [51]. The syndrome does not correlate
with previous or current markers of HPT, and its pathogenesis is
not known. One can only speculate on its relation with the next
two syndromes that I will discuss.
A vascular bone necrosis. One of the most disabling skeletal
complications of renal transplantation, avascular bone necrosis
(ABN), was first described more than 30 years ago [55]. As the
patient presented today exemplifies, this complication usually
appears between six months and the second year after transplan-
tation; the maximal incidence is in the first year [56—63]. Clini-
cally, it presents with pain in the hip, which is by far the most
frequently affected site [57]. Pain is severe enough to impede
walking. Both hips generally are affected, and several other bones
are affected in more than 30% of patients [57]. Several papers
have reported a decreasing incidence of this complication, from
about 30% prior to the introduction of cyclosporine down to
0%—4% since the introduction of cyclosporine [60—63], but
several other factors also are associated with the lower incidence
of ABN. These include lower steroid doses [60], better control of
pre-transplant HPT [62], and better clinical and nutritional con-
dition of the patient at the time of transplantation [59].
The pathogenesis of ABN is not entirely clear [64]. Infiltration
by lipid-laden cells producing high tissue pressure inside the
femoral head, in turn leading to an impediment in blood perfusion
and the resulting ischemic tissue necrosis, seems to be the most
accepted hypothesis [64]. This local phenomenon has been cor-
roborated by direct pressure measurement during core decom-
pression procedures [64]. The role played in the pathogenesis of
ABN by factors other than steroids, such as HPT, nutrition,
prolonged bed rest, and cytokines, is not understood. Diagnosis
usually is made by imaging techniques; plain radiographs usually
demonstrate only advanced ABN, as evidenced by areas of
subcortical condensation and later cortical fractures and collapse.
Bone scanning reveals earlier but nonspecific findings [65]. Nu-
clear magnetic imaging seems to be the method of choice for
diagnosis, as it allows for earlier detection and prognostic infer-
ences [66, 67]. When the lesions are recognized in their early
stages, before the appearance of cortical fractures and collapses,
a core decompression procedure can offer relief in some instances
[68, 69]. It brings immediate pain relief, but it has not been shown
to change the course of bone destruction [70]. Collapsed lesions
and those associated with degenerative joint changes are better
managed by total hip replacement [71].
Immunosuppression-related bone disease. Also called post-trans-
plant osteopenia [72], immunosuppression-related bone disease(IRBD) is defined in terms of low bone-mineral density as
assessed by dual photon absorptiometry or computerized densi-
tometry, mostly of the axial skeleton. Many groups, including our
own, are greatly concerned because IRBD has appeared in many
patients and is thought to be progressive and associated with a
higher incidence of bone fracture [73—81]. Horber and coworkers
calculated, on the basis of determinations of bone mineral content
by dual-energy, x-ray absorptiometry, that the average transplant
patient loses approximately 40 g (10%) of bone calcium salts,
mostly from the trabecular compartment, during the first five
months of having a functioning graft [76]. The attainment of a
normal "peak bone mass" can be compromised by many disease
conditions occurring during the first three decades of life [82]. Not
surprisingly, then, we found a positive correlation between bone-
mineral density and age at transplantation [79]. Thus, early,
pre-transpiant factors could influence post-transplant bone min-
eral content [79]. Nevertheless, we do not have a clear under-
standing of the pathogenesis and natural history of IRBD, be-
cause data from bone biopsies are scant. Several investigators
have shown that vertebral bone-mineral density falls dramatically,
some 6% to 10% from the pre-transplant levels, by the sixth
month post transplantation [72—74]. This decline is already appar-
ent by the third month [73] and continues to decline for as long as
18 months. These findings led Bagni and colleagues to suggest
that this loss of bone mineral content is permanent and progres-
sive [77]. In more prolonged observations, however, we and others
have noted that bone-mineral content reverted to basal levels by
the second year [76, 78, 80]. Moreover, studies of patients at
various time periods since renal transplantation (including many
after several years) found that the demineralization is not pro-
gressive, is not a universal phenomenon, and bears no relationship
to time since transplantation, time on hemodialysis, or patient age
[79—81]. Some investigators have noted a correlation between the
fall in bone-mineral density and the severity of pre-transplant
HPT [74, 83—85]. This observation is most intriguing because
trabecular or spongy bone of the axial skeleton is not the site most
affected in HPT bone disease [86]. A lesser degree of cortical
bone-mineral content loss also has been reported; it is seen less
frequently and it resolves fairly rapidly [73—76].
Many [78, 81, 84] but not all [72, 74, 79] studies have found a
correlation between the total cumulative dose of steroids and the
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Table 3. Systemic and local effects of steroids on hone and mineral
metabolism
Hormonal disturbances
Decreased production of gonadal and pituitary hormones
Impairment of growth hormone anabolic effects
Impairment in vitamin D action
Disturbances in renal calcium and phosphate handling
Increased urinary calcium excretion
Increased urinary phosphate excretion
Alteration in intestinal calcium absorption
Non-vitamin D-mediated decrease
Local effects on bone metabolism
Inhibition of osteoblast activity
Suppression of procollagen and osteocalcin production
Increased bone resorption
Inhibition of cytokine gene expression (IL-I, IL-6, TNF, TGFJ3)
Increased sensitivity of bone to PTH
amount of bone mineral loss; still another study noted a correla-
tion only with the number of acute rejection episodes treated with
intravenous steroid pulses [78]. Wolpaw et a! showed a significant
negative correlation between the total cumulative steroid dose
and the adjusted vertebral bone density; this correlation was
evident only in patients who had received more than 30 g of the
drug [81]. Torres et al have impressive evidence that pre-trans-
plant hyperparathyroidism is the main determinant of early
vertebral bone mineral loss, but that the recovery of bone mineral
content after the first year following transplantation is associated
with the presence of the so-called "favorable" common alleles
(bb) of the vitamin-D receptor; these data strongly suggest a
genetic determinant as the main factor in late post-transplant
bone density [85].
As I stated earlier, our understanding of this entity is limited
because few studies have included bone biopsies with dynamic
bone histomorphometric evaluation. The 1991 study by Julian et
al that included repeated bone biopsies at six months post
transplantation disclosed resolving osteitis fibrosa with "de-novo"
development of adynamic bone disease [721. Velasquez-Forero
and colleagues reported adynamic bone disease to be the most
frequent finding in bone biopsies performed in late (mean, 84
months) post-transplant periods in patients with normal renal
function and low bone-mineral density [871. They incriminated
steroids and bone iron deposits as the most likely causes of the low
turnover hone disease. Also, Sherrard and coworkers studied
specimens from hone biopsies performed before and at 18 months
post transplantation in 26 patients and noted a diminution of
resorption and osteoclast activity with evidence of "uncoupling"
of bone formation and bone dissolution, which they attributed to
steroids [88].
Glucocorticoids have long been known to have deleterious
effects on bone [reviewed in 15, 891. Clinical manifestations
include bone demineralization, bone pain, and fractures, which
occur more commonly in vertebral bone [89]. These effects are
time- and dose-dependent. Although these side effects occur even
with low-dose anti-inflammatory therapy [90], they are less prev-
alent [911 or absent [92] when steroids are administered as
replacement therapy. The time course, localization, and recovery
of steroid-induced osteopenia in non-transplant patients is quite
similar to that in renal transplant patients [108, 109]. The mech-
anisms of steroids' effects on bone include several systemic and
local factors (Table 3), but these mechanisms are beyond the
scope of this review.
Of particular interest in renal transplant patients are the effects
on the expression of cytokine genes. Recent information has
surfaced regarding cytokines' effects on bone metabolism in
normal and disease conditions [93, 94], including renal osteodys-
trophy [95]. Glucocorticoids suppress expression of the bone-
resorbing cytokines, IL-i, IL-6, and TNF; but glucocorticoids also
suppress TGF/3, which promotes bone formation [96]. During the
rejection process, blood levels of IL-i, IL-6, and TNF can rise [971
and thus can exert their effects on target bone cells. In short, when
a patient is receiving glucocorticoid therapy for an inflammatory
disease, the net effect on bone is the result of the complex
interaction of the drug and the cytokines IL-i, IL-6, TNF, and
TGF)3.
But transplant patients are usually immunosuppressed with
another drug that can affect bones: cyclosporine. The develop-
ment of high-turnover bone disease from cyclosporine in a rat
model has caused much concern [98], but some authors do not
attach any importance to the clinical relevance of such a mecha-
nism [99]. Moreover, the immunosuppressive effect of cyclospor-
inc entails the activation of nuclear transcription factors that in
turn induce production of IL-6, one of the most potent bone-
resorbing agents [100, 1011. Unfortunately, no experimental
model is yet available in which resolving uremic bone disease has
been studied in the company of steroid and cyclosporine admin-
istration. Clearly, we need more information to better define the
natural history, pathogenesis, diagnosis, and treatment of immu-
nosuppression-related bone disease.
QUESTIONS AND ANSWERS
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts, USA): You sug-
gested that the extracellular calcium-sensing receptor might be
involved in the pathophysiology of the hyperparathyroidism asso-
ciated with end-stage renal disease. Does any evidence indicate
that, indeed, the receptor either has different characteristics or is
dysregulated in this disorder?
DR. MA5sARI: As I mentioned, Dr. Slatopolsky's group recently
published a paper describing, in a model of vitamin-D deficient
rat, that expression of the calcium-sensing receptor in renal and
PTH gland cells is upregulated by calcitriol [7]. Although I am not
aware of any published work investigating these phenomena in
uremic models, differential expression of this receptor probably is
one of the mechanisms involved in uremic hyperparathyroidism.
DR. MAmAs: I was interested in your observation that admin-
istration of potassium citrate increases urinary aluminum excre-
tion. As you know, administered citrate is rapidly oxidized to
bicarbonate and induces bicarbonaturia. Any elevation in urinary
citrate excretion largely reflects changes in renal metabolism
rather than excretion of administered citrate. Moreover, citrate
increases intestinal aluminum absorption. Did your patients have
bicarbonaturia? Did administration of bicarbonate increase their
urinary aluminum excretion? Also, have you tested administration
of sodium citrate, rather than potassium citrate?
DR. MASSARI: In humans, the fractional excretion of citrate is
10% to 35%. It is known that the reabsorbed citrate is rapidly
oxidized to bicarbonate [102], but urinary citrate increases sub-
stantially after an oral load [1021. We have not looked for the
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presence of bicarbonaturia after the oral administration of potas-
sium citrate. We have not yet tested the effect of sodium citrate or
sodium bicarbonate on urinary aluminum excretion. Aluminum
does not seem to have an affinity for bicarbonate [103]. At the
prevailing pH of plasma, citrate behaves as a trivalent anion.
Consequently, it could be that in our studies we are obtaining a
chelation effect on tissue aluminum, a complex that is readily
filtered and excreted in urine. Note that aluminum has a very high
affinity for citrate [103]. We cannot exclude the possibility that our
results are due to interference with the tubular reabsorption of
aluminum.
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston): Could you comment on the specific causes of
non-PTH-induced phosphaturia after renal transplantation?
DR. MASSARI: Hypophosphatemia and hyperphosphaturia are a
common finding after renal transplantation [18]. Several years
ago, Rosenbaum et al showed that transplant patients with
hypophosphatemia had renal phosphate wasting that could not be
explained on the basis of their PTH levels and that the high
phosphate clearance persisted after PTH suppression induced by
calcium infusion [20]. They postulated a tubular defect in phos-
phate reabsorption or a heightened sensitivity to PTH as the
explanation for these findings. More recently, Higgins et a! [23]
and Vrtovsnik and coworkers [104] showed that steroids have a
marked phosphaturic effect and that they appear to be the main
factor in post-transplant, non-PTH induced, hypophosphatemia.
Decreased tubular reabsorption of phosphate during post-trans-
plant acute tubular necrosis could contribute to these phenomena
in early post-transplant periods, as could other drugs like acyclo-
vir, which also has a phosphaturic effect [105].
DR. MANUEL MARTINEZ-MALDONADO (Vice Chair and Profrssor
of Medicine, Emory University, Atlanta, Georgia, USA): Is there any
evidence that aluminum can affcct the calcium sensor either by
altering its conformation or substituting for calcium? Could this in
turn affect PTH secrction?
DR. MASSARI: In a recent Nephrology Forum, Hebert noted
that the particular molecular conformation of the calcium-sensing
receptor makes it well suited for binding with other bivalent and
trivalent cations [1061. Although I am not aware of any informa-
tion regarding interaction of aluminum with the calcium-sensing
receptor, what you mention is a very attractive possibility that
merits further investigation.
DR. SAULO KLAHR (Simon Professor and Co-chairman, Depart-
ment of Medicine, Washington University School of Medicine, St.
Louis, Missouri, USA): There is no question that aluminum
directly affects PTH secretion, as Slatopolsky et al showed many
years ago [107]. I just want to make some general comments on
the overall issue of secondary hyperparathyroidism and bone
disease. The natural history of this disease has changed substan-
tially since the mid-1960s. Perhaps our group was overzealous in
terms of treating dialysis patients aggressively to bring PTH down
to normal values. We know now that uremic patients need PTH
levels two to three times the normal values to have a nearly
normal bone metabolism and that normal levels of PTH in these
patients lead to adynamic bone disease. What should the PTH
level be in a renal transplant recipient?
DR. MASSARI: This is certainly a very important point, Dr.
Klahr. We do not know what the appropriate level of PTH should
be after renal transplantation, but I would guess that the problem
is confined to those patients with persistently poor renal function
and those who received high doses of immunosuppressive drugs.
Nevertheless, if the studies by Sherrard and colleagues are
confirmed [88], we might have to re-evaluate our concept of
appropriate PTH levels for patients with normal renal function
and adynamic, immunosuppression-related bone disease.
DR. MADIAS: You showed a correlation between GFR and
serum phosphate and calcitriol levels in patients following trans-
plantation. What about patients with persistent post-transplanta-
tion hyperparathyroidism, hypophosphatemia, and well-main-
tained graft function? Do these patients have supranormal levels
of calcitriol?
DR. MASSARI: Garabedian et a! showed that in children with
sub-normal renal function, calcitriol levels were not appropriate
for the degree of hypophosphatemia [12]. Moreover, in spite of
the fact that several patients had high levels of calcitriol, a
"normal type" correlation did not exist between serum PTH and
calcitriol levels. It seems that the main determinant of post-
transplant calcitriol levels is the GFR [13].
DR. J. CARLO5 AYUS (Professor of Medicine, Baylor College of
Medicine, Houston, Texas, USA): What are the indications for
treatment with calcitriol and/or calcium supplements in transplant
patients with incomplete recovery of renal function and persistent
hyperparathyroidism? What are the indications for parathyroid-
ectomy in these patients?
DR. MASSARI: As I mentioned, post-transplant patients with
normocalcemia, hypophosphatemia, and hyperparathyroidism can
benefit from calcitriol and calcium supplements [14], but appro-
priate precautions should be taken to avoid hypercalcemia and/or
hypercalciuria. The indications for parathyroidectomy or ethanol
injection include protracted, symptomatic hypercalcemia, espe-
cially when it induces deterioration of renal function, soft-tissue
calcification, or worsening bone disease.
DR. AMANDO L. NEGRI (Staff Nephrologist, Institute for Metabolic
Research, Buenos Aires, Argentina): Cyclosporine produces high-
turnover bone disease and could contribute to immunosuppres-
sion-induced bone disease. Does tacrolimus have the same effects
on bone? Could it have a bone-sparing effect?
DR. MASSARI: Unfortunately that is not the case. Cvetkovic et al
have recently shown that tacrolimus produces a similar disorder
[108]. This is not surprising if you consider the immunosuppres-
sant mechanism of the drug [100].
DR. HoRAclo J. ADROGUE (Professor of Medicine, Baylor College
of Medicine): It seems to me that the comparison of bone and
skeletal manifestations after renal transplantation with bone and
skeletal changes following heart and liver transplantation might
elucidate the role of immunosuppressive drugs independent of
other factors like hyperparathyroidism, aluminum, etc. Thus, I
suppose that if cyclosporine is responsible for the painful legs
syndrome after renal transplantation, which you indicated is quite
common, such a syndrome also should be evident after transplan-
tation of other organs if the patient receives the same drugs.
DR. MASSARI: Your observation is very interesting. Information
on bone disease after heart or liver transplantation has been
surfacing recently. Although I am not aware of any description of
the painful legs syndrome after non-renal transplantation, severe
osteopenia and a high incidence of bone fracture have been
reported [109, 110]. However, pre-transpiant clinical conditions,
prolonged hospitalization time, as well as the multiple drugs
administered to these patients in the post-transplant period all
contribute to making comparison difficult.
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DR. HARRINGTON: You said that fractional aluminum excretion
increased in patients with acute tubular necrosis. Was this only
during the period of ATN, or did it last longer? Was absolute
excretion higher than in the controls during this same period?
DR. MASSARL: In patients with post-transplant acute tubular
necrosis, the difference in fractional excretion of aluminum, as
well as in the absolute excretion rate, was still present four weeks
after transplantation, but it vanished thereafter.
DR. RoDoLFo S. MARTIN (Instituto de Investigaciones Médicas,
Buenos Aires, Argentina): In the patient presented today, would
you say that the appearance of bilateral symptomatic osteonecro-
sis occurred rather early after transplantation? Don't you think
that osteomalacia played a more important pathogenetic role than
did avascular necrosis?
DR. MASSARI: This patient had bilateral necrosis of the hip at 15
months after transplantation, about the time of maximal incidence
of this complication. Uremic bone disease might play a role in this
entity, but it has been reported quite infrequently in dialysis
patients.
DR. MADIA5: Have biphosphonates, and in particular alendro-
nate, been used in the treatment of post-transplant osteopenia?
DR. MAS5ARI: The abstract book for the 1996 ASN meeting in
New Orleans contains a report from Dr. Almond from London
showing the results of a prospective study with pamidronate to
prevent bone loss in these patients. After one year of treatment,
treated patients had a marked diminution in bone loss compared
to controls. This is the first study utilizing biphosphonates suc-
cessfully in this condition [111].
DR. MADLAS: You showed data indicating that increased body
aluminum correlates with increased mortality rates. As you know,
aluminum bone disease tends to be more severe in diabetics.
Might the correlation reflect the increased propensity of diabetics
to develop this disorder rather than the adverse effect of alumi-
num per se on survival?
DR. MASSARI: The data published by Chazan et al come from a
population of more than 10,000 dialysis patients. Applying the
Cox model, these researchers showed that diabetes and serum
aluminum levels were independent risk factors for survival [36].
DR. HoRAclo REPE1TO (Chief Pediatric Service, Hospital Nacio-
nalA. PosadaA Buenos Aires, Argentina): Would you comment on
the possible explanation for the association between aluminum
intoxication and what seems to be a decrease in the immune
response against infections?
DR. MAsSARI: I think it is an unsettled issue as yet. Tzanno-
Martins et al had shown that aluminum-treated rats display a
decreased immune response to mitogen as assessed by the lym-
phoproliferative response, with a decreased lymphocyte helper!
cytotoxic ratio and a reduction in IL-2 production [38]. Further
studies are needed to clarify the mechanism.
DR. PEDRO SZYLMAN: (Poria Hospital Renal Unit, Tiberias,
Israel): Do you have information about drug abuse as a risk factor
for femoral head aseptic necrosis in patients who have received
transplants? Cyclosporine substantially reduces the incidence of
post-transplant hone disease and avascular necrosis, but 1 wonder
whether this can be related to a reduction in steroid dosage and
general better outcome.
DR. MASSARI: Heavy alcohol ingestion has been associated with
avascular bone necrosis. I do not know of any other abused drug
implicated with the syndrome. As to the mechanism of the
cyclosporine-associated fall in the incidence of avascular bone
necrosis, a reduction in steroid dosage seems to be the main
factor, but we cannot rule out cytokine-related effects.
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